The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients

Transplant Immunology

Volumn 14, Issue 1, 2005, Pages 37-42

  Zheng, H X ^a   Zeevi, A ^b   McCurry, K ^b   Schuetz, E ^c   Webber, S ^b   Ristich, J ^b   Zhang, J ^c   Iacono, A ^b   Dauber, J ^b   McDade, K ^b   Zaldonis, D ^b   Lamba, J ^c   Burckart, G J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cytochrome P450 3A5; Cytokines; Multidrug resistance; Multivariate regression; P glycoprotein; Polymorphism; Transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYTOCHROME P450 3A5; CYTOKINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; TACROLIMUS;

AGE DISTRIBUTION; ALGORITHM; ALLELE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; DRUG DISPOSITION; GENETIC SCREENING; GENOTYPE; HLA SYSTEM; HUMAN; LUNG BIOPSY; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; SEX ROLE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 20144387219     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2004.11.001     Document Type: Article

References (41)

1. S. Tamura, A. Ohike, R. Ibuki, G.L. Amidon, and S. Yamashita Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats J. Pharm. Sci. 91 3 2002 719 729
2. S. Masuda, S. Uemoto, T. Hashida, Y. Inomata, K. Tanaka, and K. Inui Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient Clin. Pharmacol. Ther. 68 1 2000 98 103
3. Y. Hashimoto, H. Sasa, M. Shimomura, and K. Inui Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats Pharm. Res. 15 10 1998 1609 1613
4. A. Lo, and G.J. Burckart P-glycoprotein and drug therapy in organ transplantation J. Clin. Pharmacol. 39 10 1999 995 1005
5. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmoller, and A. Johne Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc. Natl. Acad. Sci. U. S. A. 97 7 2000 3473 3478
6. M. Hitzl, S. Drescher, H. van der Kuip, E. Schafeller, J. Fischer, and M. Schwab The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells Pharmacogenetics 11 4 2001 293 298
7. N. von Ahsen, M. Richter, C. Grupp, B. Ringe, M. Oellerich, and V.W. Armstrong No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients Clin. Chem. 47 6 2001 1048 1052
8. I. Cascorbi, T. Gerloff, A. Johne, C. Meisel, S. Hoffmeyer, and M. Schwab Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects Clin. Pharmacol. Ther. 69 3 2001 169 174
9. M. Tanabe, I. Ieiri, N. Nagata, K. Inoue, S. Ito, and Y. Kanamori Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene J. Pharmacol. Exp. Ther. 297 3 2001 1137 1143
10. H. Zheng, S. Webber, A. Zeevi, E. Schuetz, J. Zhang, and P. Bowman Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms Am. J. Transplant 3 4 2003 477 483
11. H. Zheng, S. Webber, A. Zeevi, E. Schuetz, J. Zhang, and J. Lamba The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients Hum. Immunol. 63 9 2002 765 770
12. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, and J. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat. Genet. 27 4 2001 383 391
13. B.D. Haehner, J.C. Gorski, M. Vandenbranden, S.A. Wrighton, S.K. Janardan, and P.B. Watkins Bimodal distribution of renal cytochrome P450 3A activity in humans Mol. Pharmacol. 50 1 1996 52 59
14. H. Zheng, A. Zeevi, E. Schuetz, J. Lamba, K. McCurry, and B.P. Griffith Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism J. Clin. Pharmacol. 44 2 2004 135 140
15. M.R. Awad, S. Webber, G. Boyle, C. Sturchioc, M. Ahmed, and J. Martell The effect of cytokine gene polymorphisms on pediatric heart allograft outcome J. Heart Lung Transplant. 20 6 2001 625 630
16. A.J. Bathgate, V. Pravica, C. Perrey, G. Therapondos, J.N. Plevris, and P.C. Hayes The effect of polymorphisms in tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in acute hepatic allograft rejection Transplantation 69 7 2000 1514 1517
17. T. Aziz, P. Hasleton, A.W. Hann, N. Yonan, A. Deiraniya, and I.V. Hutchinson Transforming growth factor beta in relation to cardiac allograft vasculopathy after heart transplantation J. Thorac. Cardiovasc. Surg. 119 4 Pt 1 2000 700 708
18. I.V. Hutchinson, D. Turner, D. Sankaran, M. Awad, V. Pravica, and P. Sinnott Cytokine genotypes in allograft rejection: guidelines for immunosuppression Transplant. Proc. 30 8 1998 3991 3992
19. I.V. Hutchinson, V. Pravica, C. Perrey, and P. Sinnott Cytokine gene polymorphisms and relevance to forms of rejection Transplant. Proc. 31 1-2 1999 734 736
20. I.V. Hutchinson, D.M. Turner, D. Sankaran, M.R. Awad, and P.J. Sinnott Influence of cytokine genotypes on allograft rejection Transplant. Proc. 30 3 1998 862 863
21. D. Sankaran, A. Asderakis, S. Ashraf, I.S. Roberts, C.D. Short, and P.A. Dyer Cytokine gene polymorphisms predict acute graft rejection following renal transplantation Kidney Int. 56 1 1999 281 288
22. S. Nadel, M.J. Newport, R. Booy, and M. Levin Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease J. Infect. Dis. 174 4 1996 878 880
23. Z. Liu, S. Colpaert, G.R. D'Haens, A. Kasran, M. de Boer, and P. Rutgeerts Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production J. Immunol. 163 7 1999 4049 4057
24. M.F. Moffatt, and W.O. Cookson Tumour necrosis factor haplotypes and asthma Hum. Mol. Genet. 6 4 1997 551 554
25. M. Lazarus, A.H. Hajeer, D. Turner, P. Sinnott, J. Worthington, and W.E. Ollier Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus J. Rheumatol. 24 12 1997 2314 2317
26. M.J. Rood, M.V. van Krugten, E. Zanelli, M.W. van der Linden, V. Keijsers, and G.M. Schreuder TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus Arthritis Rheum. 43 1 2000 129 134
27. H.X. Zheng, G.J. Burckart, K. McCurry, S. Webber, J. Ristich, and A. Iacono Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation J. Heart Lung Transplant. 23 5 2004 541 546
28. L.Z. Benet, T. Izumi, Y. Zhang, J.A. Silverman, and V.J. Wacher Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery J. Control. Release 62 1-2 1999 25 31
29. V.J. Wacher, C.Y. Wu, and L.Z. Benet Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy Mol. Carcinog. 13 3 1995 129 134
30. W.E. Evans, and J.A. Johnson Pharmacogenomics: the inherited basis for interindividual differences in drug response Annu. Rev. Genomics Hum. Genet. 2 2001 9 39
31. J.M. Rusnak, R.M. Kisabeth, D.P. Herbert, and D.M. McNeil Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care Mayo Clin. Proc. 76 3 2001 299 309
32. A.D. Roses Pharmacogenetics and the practice of medicine Nature 405 6788 2000 857 865
33. E.S. Vesell Advances in pharmacogenetics and pharmacogenomics J. Clin. Pharmacol. 40 9 2000 930 938
34. T. Hashida, S. Masuda, S. Uemoto, H. Saito, K. Tanaka, and K. Inui Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation Clin. Pharmacol. Ther. 69 5 2001 308 316
35. R.W. Johnstone, E. Cretney, and M.J. Smyth P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death Blood 93 3 1999 1075 1085
36. A. Vail, S.M. Gore, B.A. Bradley, D.L. Easty, C.A. Rogers, W.J. Armitage Collaborating surgeons Conclusions of the corneal transplant follow up study Br. J. Ophthalmol. 81 8 1997 631 636 [see comment]
37. D.G. Renlund, E.M. Gilbert, J.B. O'Connell, W.A. Gay Jr., K.W. Jones, and N.A. Burton Age-associated decline in cardiac allograft rejection Am. J. Med. 83 3 1987 391 398
38. R.K. Zetterman, S.H. Belle, J.H. Hoofnagle, S. Lawlor, Y. Wei, and J. Everhart Age and liver transplantation: a report of the liver transplantation database Transplantation 66 4 1998 500 506
39. B.A. Bradley, S. Takemoto, D. Gjertson, E. Reed, and M. Cecka Elderly transplant recipients may require less immunosuppression Transplant. Proc. 33 1-2 2001 1115 1116
40. G.I. Snell, A. De Hoyos, T. Winton, and J.R. Maurer Lung transplantation in patients over the age of 50 Transplantation 55 3 1993 562 566
41. P.G. Middleton, P.R. Taylor, G. Jackson, S.J. Proctor, and A.M. Dickinson Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants Blood 92 10 1998 3943 3948